These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 11426792)
41. Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy? Kereiakes DJ Am Heart J; 1999 Jul; 138(1 Pt 2):S39-46. PubMed ID: 10385790 [TBL] [Abstract][Full Text] [Related]
42. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997 [TBL] [Abstract][Full Text] [Related]
43. Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab. Cote AV; Berger PB; Holmes DR; Scott CG; Bell MR Mayo Clin Proc; 2001 Sep; 76(9):890-6. PubMed ID: 11560299 [TBL] [Abstract][Full Text] [Related]
44. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes. Exaire JE; Lincoff AM J Thromb Haemost; 2004 Jan; 2(1):7-9. PubMed ID: 14717958 [No Abstract] [Full Text] [Related]
45. The benefits and risks of abciximab, eptifibatide, or tirofiban during PCI: class effects or do they differ? Zijlstra F Catheter Cardiovasc Interv; 2009 Feb; 73(2):222-3. PubMed ID: 19156883 [No Abstract] [Full Text] [Related]
46. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843 [TBL] [Abstract][Full Text] [Related]
47. Emergency coronary artery bypass grafting (CABG) after failed coronary artery intervention--caution regarding the combined use of aspirin, ticlopidine and abciximab. Alvarez JM; Harper RW; Peverill RE Aust N Z J Med; 1998 Aug; 28(4):463-4. PubMed ID: 9777116 [No Abstract] [Full Text] [Related]
48. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A; N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302 [TBL] [Abstract][Full Text] [Related]
49. Routine use of abciximab in coronary stenting? Stables RH Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267 [No Abstract] [Full Text] [Related]
50. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation. Bertrand OF; De Larochellière R; Rodés-Cabau J; Proulx G; Gleeton O; Nguyen CM; Déry JP; Barbeau G; Noël B; Larose E; Poirier P; Roy L; Circulation; 2006 Dec; 114(24):2636-43. PubMed ID: 17145988 [TBL] [Abstract][Full Text] [Related]
51. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting. Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635 [TBL] [Abstract][Full Text] [Related]
52. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. EPISTENT Investigators Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272 [TBL] [Abstract][Full Text] [Related]
53. Pulmonary hemorrhage after percutaneous coronary intervention with abciximab therapy. Choi RK; Lee NH; Lim DS; Hong Sk; Hwang HK Mayo Clin Proc; 2002 Dec; 77(12):1340-3. PubMed ID: 12479522 [TBL] [Abstract][Full Text] [Related]
54. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). Assali AR; Salloum J; Sdringola S; Moustapha A; Ghani M; Hale S; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR Am J Cardiol; 2001 Oct; 88(8):884-6, A6. PubMed ID: 11676953 [No Abstract] [Full Text] [Related]
55. Delayed immune-mediated thrombocytopenia after re-exposure to abciximab therapy. Rasti M; Blostein M Can J Cardiol; 2011; 27(6):869.e13-4. PubMed ID: 21885241 [TBL] [Abstract][Full Text] [Related]